The dangerous fat you can’t see: new research reveals its heart impact
Live Forever Club - 24-Nov-2025Visceral fat flags early artery damage, revealing new targets for prevention
Join the club for FREE to access the whole archive and other member benefits.
Visceral fat flags early artery damage, revealing new targets for prevention
Wearable PpgAge predicts biological age and flags higher heart disease risk
Targeted epigenetic editing could deliver durable, precise therapies for aging-related diseases
Lila Sciences aims to speed up breakthroughs by pairing powerful AI with massive robotic labs
MRI plus PSA and saliva tests may boost accuracy of early prostate cancer detection
Spermidine shows early signs of improving memory, but clinical results remain inconsistent
Metabolic fingerprints from 500,000 people reveal risks 10–15 years before illness
Lab-grown corneal implant safely integrated and returned sight in initial human use
Natural nozzle enables micro-scale 3D printing at under one dollar each
UPFs tied to higher risks of diabetes, heart disease and early death, experts warn
New Hevolution–Nanobiosym deal accelerates AI-driven metabolic and ageing diagnostics
A widower’s new relationship after cryopreserving his wife ignites a fierce ethical debate in China
New DNA origami nanorobots can store energy and perform multistep tasks without external power
Boosting telomerase with engineered RNA reduced ageing and fibrosis in human lung tissue
AI-driven experiments will map how molecules penetrate tough Gram-negative bacteria
First-line nivolumab doubles typical response rates in inoperable basal cell carcinoma
Ageing clocks reveal 27% more drug targets, speeding multi-disease therapy
Startup uses transcription factor mapping to find disease-modifying treatments for neurodegeneration
Walking performance in non-diabetic PAD patients remained unchanged despite metformin treatment
A centuries-old Greenland shark reveals how slow life in the deep sea fuels extreme longevity
AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
The company hopes to begin human testing in the next few years
Insilico’s AI cut drug discovery to 18 months, spurring Lilly’s investment
Graphene-based BCIs use Azure AI to adapt in real time for Parkinson’s and stroke therapy
Low-dose antibiotics trigger microbes to make metabolites that improve longevity and metabolism